{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:10:17Z","timestamp":1776384617110,"version":"3.51.2"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ejmech.2021.114061","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T20:20:22Z","timestamp":1640031622000},"page":"114061","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Discovery of new and highly effective quadruple FFA1 and PPAR\u03b1\/\u03b3\/\u03b4 agonists as potential anti-fatty liver agents"],"prefix":"10.1016","volume":"229","author":[{"given":"Zongtao","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shixuan","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongyu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinqian","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liming","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8067-9700","authenticated-orcid":false,"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.114061_bib1","article-title":"The therapeutic potential of resveratrol: a review of clinical trials","volume":"1","author":"Berman","year":"2017","journal-title":"NPJ Precis Oncol."},{"key":"10.1016\/j.ejmech.2021.114061_bib2","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1016\/j.cgh.2014.02.024","article-title":"Resveratrol does not benefit patients with nonalcoholic fatty liver disease","volume":"12","author":"Chachay","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2021.114061_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease: a population-based cohort study","volume":"129","author":"Adams","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2021.114061_bib4","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.21327","article-title":"Long-term follow-up of patients with NAFLD and elevated liver enzymes","volume":"44","author":"Ekstedt","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2021.114061_bib5","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1053\/j.gastro.2017.01.003","article-title":"Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation","volume":"152","author":"Goldberg","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejmech.2021.114061_bib6","doi-asserted-by":"crossref","first-page":"154203","DOI":"10.1016\/j.metabol.2020.154203","article-title":"Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis","volume":"111S","author":"Polyzos","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.ejmech.2021.114061_bib7","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1002\/jps.22639","article-title":"Free fatty acid receptors FFAR1 and GPR120 as novel therapeutic targets for metabolic disorders","volume":"100","author":"Hara","year":"2011","journal-title":"J.\u00a0Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2021.114061_bib8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature01478","article-title":"Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40","volume":"422","author":"Itoh","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.114061_bib9","doi-asserted-by":"crossref","first-page":"11303","DOI":"10.1074\/jbc.M211495200","article-title":"The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids","volume":"278","author":"Briscoe","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.114061_bib10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/pr.108.00802","article-title":"Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions","volume":"60","author":"Stoddart","year":"2008","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2021.114061_bib11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1124\/mol.109.055244","article-title":"Molecular pharmacology of promiscuous seven transmembrane receptors sensing organic nutrients","volume":"76","author":"Wellendorph","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.114061_bib12","doi-asserted-by":"crossref","first-page":"C1518","DOI":"10.1152\/ajpcell.00368.2008","article-title":"Linoleic acid stimulates gluconeogenesis via Ca2+\/PLC, cPLA2, and PPAR pathways through GPR40 in primary cultured chicken hepatocytes","volume":"295","author":"Suh","year":"2008","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ejmech.2021.114061_bib13","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.jnutbio.2011.07.006","article-title":"Oleic acid activates peroxisome proliferator-activated receptor \u03b4 to compensate insulin resistance in steatotic cells","volume":"23","author":"Wu","year":"2012","journal-title":"J.\u00a0Nutr. Biochem."},{"key":"10.1016\/j.ejmech.2021.114061_bib14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1530\/JME-14-0003","article-title":"Activation of free fatty acid receptor 1 improves hepatic steatosis through a p38-dependent pathway","volume":"53","author":"Ou","year":"2014","journal-title":"J.\u00a0Mol. Endocrinol."},{"key":"10.1016\/j.ejmech.2021.114061_bib15","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.ajpath.2018.01.009","article-title":"A\u00a0newly discovered antifibrotic pathway regulated by two fatty acid receptors: GPR40 and GPR84","volume":"188","author":"Gagnon","year":"2018","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejmech.2021.114061_bib16","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/13543784.2016.1189530","article-title":"Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development","volume":"25","author":"Li","year":"2016","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2021.114061_bib17","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/med.21441","article-title":"Free fatty acid receptor 1 (FFAR1) as an emerging therapeutic target for type 2 diabetes mellitus: recent progress and prevailing challenges","volume":"38","author":"Li","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2021.114061_bib18","series-title":"Current Status of GPR40\/FFAR1 Modulators in Medicinal Chemistry (2016-2019): a Patent Review","first-page":"1","author":"Li","year":"2019"},{"key":"10.1016\/j.ejmech.2021.114061_bib19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1124\/jpet.120.000046","article-title":"The GPR40 full agonist SCO-267 improves liver parameters in a mouse model of nonalcoholic fatty liver disease without affecting glucose or body weight","volume":"375","author":"Ookawara","year":"2020","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2021.114061_bib20","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1111\/bph.14980","article-title":"HWL-088, a new potent free fatty acid receptor 1 (FFAR1) agonist, improves glucolipid metabolism and acts additively with metformin in ob\/ob diabetic mice","volume":"177","author":"Chen","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.114061_bib21","doi-asserted-by":"crossref","first-page":"103209","DOI":"10.1016\/j.bioorg.2019.103209","article-title":"Discovery of HWL-088: a highly potent FFA1\/GPR40 agonist bearing a phenoxyacetic acid scaffold","volume":"92","author":"Li","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2021.114061_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24142545","article-title":"PPARs as nuclear receptors for nutrient and energy metabolism","volume":"24","author":"Hong","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2021.114061_bib23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13148-015-0149-2","article-title":"Promoter methylation status and expression of PPAR-\u03b3 gene are associated with prognosis of acute-on-chronic hepatitis B liver failure","volume":"7","author":"Zhao","year":"2015","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.ejmech.2021.114061_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19072013","article-title":"Ppar\u03b2\/\u03b4: linking metabolism to regeneration","volume":"19","author":"Magadum","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2021.114061_bib25","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.semcdb.2012.01.003","article-title":"PPARs: fatty acid sensors controlling metabolism","volume":"23","author":"Poulsen","year":"2012","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2021.114061_bib26","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/CIRCULATIONAHA.104.475673","article-title":"Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets","volume":"115","author":"Brown","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ejmech.2021.114061_bib27","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1172\/JCI6223","article-title":"Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting","volume":"103","author":"Kersten","year":"1999","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ejmech.2021.114061_bib28","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","article-title":"Liver PPAR\u03b1 is crucial for whole-body fatty acid homeostasis and is protective against NAFLD","volume":"65","author":"Montagner","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.ejmech.2021.114061_bib29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/MOL.0b013e32835cc949","article-title":"Peroxisome proliferator-activated receptor \u03b4: a multifaceted metabolic player","volume":"24","author":"Bojic","year":"2013","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.ejmech.2021.114061_bib30","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.1093\/nar\/gkv331","article-title":"The transcriptional PPAR\u03b2\/\u03b4 network in human macrophages defines a unique agonist-induced activation state","volume":"43","author":"Adhikary","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2021.114061_bib31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1161\/01.ATV.0000252790.70572.0c","article-title":"Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist","volume":"27","author":"Sprecher","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ejmech.2021.114061_bib32","doi-asserted-by":"crossref","first-page":"15924","DOI":"10.1073\/pnas.0306981100","article-title":"Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome","volume":"100","author":"Tanaka","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2021.114061_bib33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/jcp.25804","article-title":"The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice","volume":"233","author":"Derosa","year":"2018","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.ejmech.2021.114061_bib34","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nm.3159","article-title":"PPAR\u03b3 signaling and metabolism: the good, the bad and the future","volume":"19","author":"Ahmadian","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2021.114061_bib35","first-page":"549627","article-title":"Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases","author":"Monsalve","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.ejmech.2021.114061_bib36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1262-3636(07)70083-6","article-title":"Clinical interest of PPARs ligands","volume":"30","author":"Verg\u00e8s","year":"2004","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.ejmech.2021.114061_bib37","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2019.01.067","article-title":"Role of PPAR receptor in different diseases and their ligands: physiological importance and clinical implications","volume":"166","author":"Mirza","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114061_bib38","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ejmech.2018.09.071","article-title":"Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPAR\u03b3 and PPAR\u03b4","volume":"159","author":"Li","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114061_bib39","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ejmech.2018.12.069","article-title":"Discovery of first-in-class thiazole-based dual FFA1\/PPAR\u03b4 agonists as potential anti-diabetic agents","volume":"164","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114061_bib40","doi-asserted-by":"crossref","first-page":"103254","DOI":"10.1016\/j.bioorg.2019.103254","article-title":"Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)\/PPAR\u03b4 agonists as potential anti-diabetic agents","volume":"92","author":"Li","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2021.114061_bib41","doi-asserted-by":"crossref","first-page":"104679","DOI":"10.1016\/j.phrs.2020.104679","article-title":"A\u00a0novel FFA1 agonist, CPU025, improves glucose-lipid metabolism and alleviates fatty liver in obese-diabetic (ob\/ob) mice","volume":"153","author":"Li","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2021.114061_bib42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1124\/jpet.118.255216","article-title":"RLA8-A new and highly effective quadruple PPAR-\u03b1\/\u03b3\/\u03b4 and GPR40 agonist to reverse nonalcoholic steatohepatitis and fibrosis","volume":"369","author":"Li","year":"2019","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2021.114061_bib43","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jhep.2018.03.011","article-title":"A\u00a0simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer","volume":"69","author":"Tsuchida","year":"2018","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2021.114061_bib44","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.jhep.2013.12.025","article-title":"Macrophage heterogeneity in liver injury and fibrosis","volume":"60","author":"Tacke","year":"2014","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2021.114061_bib45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/mnfr.201200589","article-title":"Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans","volume":"58","author":"Cottart","year":"2014","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.ejmech.2021.114061_bib46","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/hep.27297","article-title":"The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice","volume":"60","author":"Pawlak","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2021.114061_bib47","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hep.24341","article-title":"Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells","volume":"54","author":"Csak","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2021.114061_bib48","doi-asserted-by":"crossref","first-page":"173300","DOI":"10.1016\/j.ejphar.2020.173300","article-title":"Hepatoprotective effects of ZLY16, a dual peroxisome proliferator-activated receptor \u03b1\/\u03b4 agonist, in rodent model of nonalcoholic steatohepatitis","volume":"882","author":"Zhou","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.114061_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/jphp.13342","article-title":"HWL-088, a new and highly effective FFA1\/PPAR\u03b4 dual agonist, attenuates nonalcoholic steatohepatitis by regulating lipid metabolism, inflammation and fibrosis","author":"Hu","year":"2020","journal-title":"J.\u00a0Pharm. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.114061_bib50","doi-asserted-by":"crossref","first-page":"105035","DOI":"10.1016\/j.phrs.2020.105035","article-title":"ZLY032, the first-in-class dual FFA1\/PPAR\u03b4 agonist, improves glucolipid metabolism and alleviates hepatic fibrosis","volume":"159","author":"Li","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2021.114061_bib51","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/17474124.2018.1530110","article-title":"An update on the recent advances in antifibrotic therapy","volume":"12","author":"Tacke","year":"2018","journal-title":"Expet Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2021.114061_bib52","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","article-title":"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages(\u2606)","volume":"73","author":"Lefere","year":"2020","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2021.114061_bib53","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1021\/acs.jmedchem.7b01285","article-title":"Design, synthesis, and evaluation of a novel series of indole sulfonamide peroxisome proliferator activated receptor (PPAR) \u03b1\/\u03b3\/\u03b4 triple activators: discovery of lanifibranor, a new antifibrotic clinical candidate","volume":"61","author":"Boubia","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114061_bib54","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0168-8278(02)00073-9","article-title":"In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases","volume":"37","author":"Seki","year":"2002","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.ejmech.2021.114061_bib55","doi-asserted-by":"crossref","first-page":"R453","DOI":"10.1016\/j.cub.2014.03.034","article-title":"ROS function in redox signaling and oxidative stress","volume":"24","author":"Schieber","year":"2014","journal-title":"Curr. Biol."},{"key":"10.1016\/j.ejmech.2021.114061_bib56","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.mce.2014.08.014","article-title":"Polydatin promotes Nrf2-ARE anti-oxidative pathway through activating Sirt1 to resist AGEs-induced upregulation of fibronetin and transforming growth factor-beta1 in rat glomerular messangial cells","volume":"399","author":"Huang","year":"2015","journal-title":"Mol. Cell. Endocrinol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421009107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421009107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:34:58Z","timestamp":1759329298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421009107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":56,"alternative-id":["S0223523421009107"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.114061","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of new and highly effective quadruple FFA1 and PPAR\u03b1\/\u03b3\/\u03b4 agonists as potential anti-fatty liver agents","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.114061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114061"}}